Author

K. Vuori

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

D. Finlay· 3 shared A. Bush· 1 shared A. Deshpande· 1 shared A. J. Deshpande· 1 shared A. Khateb· 1 shared A. Ray· 1 shared A. S. Espinoza· 1 shared A. Sahoo· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. Finlay

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The effects of cell-cell orientation in modeling the hallmarks of lung cancer in vitro

A. S. Espinoza, R. N. McVicar, D. Finlay, R. Murad, K. Vuori, B. A. Grimmig, A. Bush, E. Smith, T. Mandel-Clausen, H. M. McGee, E. Y. Snyder, S. L. Leibel

This study compares 3D tumoroid and 2D cultures of lung cancer cells to assess how cell-cell orientation affects cancer-related features and finds that 3D cultures better mimic primary human lung cancer.

bioRxiv · Dec 30, 2023 · PreprintCancer Biology

RNF5 Regulation of RBBP4 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

A. Khateb, A. Deshpande, Y. Feng, J. S. Lee, I. Lazar, B. Fabre, Y. Li, D. Finlay, Y. Fujita, T. Zhang, J. Yin, I. Pass, I. Livneh, C. Burian, J. R. Mason, , Z. A. Ronai

This study shows RNF5 promotes AML growth by regulating RBBP4 and epigenetic pathways, and its inhibition enhances sensitivity to HDAC inhibitors, suggesting it as a therapeutic target and biomarker.

bioRxiv · Oct 25, 2020Cancer Biology

Exosome-mediated MIR211 modulates tumor microenvironment via the DUSP6-ERK5 axis and contributes to BRAFV600E inhibitor resistance in melanoma.

B. Lee, A. Sahoo, J. Marchica, J. Sawada, S. Sahoo, F. I. A. L. Layng, D. Finlay, J. Mazar, P. Joshi, M. Komatsu, K. Vuori, G. Powis, P. R. de Jong, A. Ray, R. J. Perera

This study shows MIR211 promotes melanoma growth and resistance to BRAF inhibitors by modulating the DUSP6-ERK5 axis via exosome transfer in the tumor microenvironment.

bioRxiv · Feb 13, 2019 · PreprintCancer Biology